Strides Pharma Gets USFDA Nod for Theophylline Tablets
By Rediff Money Desk, New Delhi Sep 06, 2024 11:19
Strides Pharma Science's arm receives USFDA approval for generic Theophylline extended-release tablets, indicated for managing chronic asthma and other respiratory conditions.
New Delhi, Sep 6 (PTI) Strides Pharma Science Ltd on Friday said its arm has received approval from the US health regulator for its generic version of Theophylline extended-release tablets indicated for management of various respiratory conditions, including chronic asthma.
The approval granted by the US Food & Drug Administration (USFDA) to Strides Pharma Global Pte Ltd, Singapore, is for generic version of Theophylline Extended-Release Tablets 300 mg and 450 mg, Strides Pharma said in a regulatory filing.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR of Schering Corp, it added.
Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
The Theophylline extended-release tablets -- 300 mg and 450 mg -- will be manufactured at the company's flagship facility in KRS Gardens in Bengaluru, the company said.
These tablets have a combined market size of about USD 11.5 million, the company said, citing IQVIA data.
The approval granted by the US Food & Drug Administration (USFDA) to Strides Pharma Global Pte Ltd, Singapore, is for generic version of Theophylline Extended-Release Tablets 300 mg and 450 mg, Strides Pharma said in a regulatory filing.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR of Schering Corp, it added.
Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
The Theophylline extended-release tablets -- 300 mg and 450 mg -- will be manufactured at the company's flagship facility in KRS Gardens in Bengaluru, the company said.
These tablets have a combined market size of about USD 11.5 million, the company said, citing IQVIA data.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 13.40 ( -11.20)
- 157313812
- Rama Steel Tubes
- 16.28 (+ 17.12)
- 52223911
- Rajnish Wellness
- 3.61 ( -1.10)
- 36560028
- GTL Infrastructure
- 2.46 ( -3.53)
- 29751238
- ARC Finance
- 1.70 (+ 4.29)
- 25015585
MORE NEWS
Swiggy Launches Incognito Mode for Private...
Swiggy introduces Incognito Mode, allowing users to place private orders on food and...
Goyal Invites Steel Industry to Discuss Unfair...
India's Commerce Minister Piyush Goyal has invited the steel industry to discuss unfair...
ISA & MIGA Launch Multi-Donor Fund for Solar...
The International Solar Alliance (ISA) and Multilateral Investment Guarantee Agency...